The story of amylin: from physiology to therapy - PubMed
4 days ago
- #amylin
- #diabetes
- #obesity
- Amylin is a glucoregulatory peptide hormone discovered in 1986.
- Pramlintide, a human amylin analogue, was approved as an adjunct treatment to insulin for type 1 and type 2 diabetes in the early 2000s.
- The therapeutic potential of amylin has been underexplored until recent renewed interest in amylin-based therapies.
- Recent advancements include preclinical and clinical data, amylin receptor pharmacology, and broader biological effects.
- Amylin-based treatments are being explored for cardiometabolic diseases, including diabetes and obesity.
- Combination therapies, such as CagriSema (amylin analogue + GLP1R analogue), are part of future treatment landscapes.
- Key challenges and milestones in amylin drug development are discussed.